Apellis Pharmaceuticals Inc
83 articles with Apellis Pharmaceuticals Inc
-
Apellis Announces FDA Acceptance and Priority Review of the New Drug Application for Pegcetacoplan for the Treatment of PNH
11/16/2020
Apellis Pharmaceuticals, Inc., a global biopharmaceutical company and leader in targeted C3 therapies, announced that the U.S. Food and Drug Administration has accepted and granted Priority Review designation for the New Drug Application for pegcetacoplan for the treatment of paroxysmal nocturnal hemoglobinuria.
-
Apellis Announces Late-Breaking Presentation of Largest Retrospective Database Study in Geographic Atrophy (GA) at AAO 2020 Virtual
11/13/2020
Apellis Pharmaceuticals today announced findings from the largest retrospective database study in geographic atrophy (GA) secondary to age-related macular degeneration (AMD). The analysis of the American Academy of Ophthalmology
-
Apellis Pharmaceuticals to Present at Upcoming Investor Conferences - Nov 11, 2020
11/11/2020
Apellis Pharmaceuticals, Inc., a global biopharmaceutical company and leader in targeted C3 therapies, announced that the company will participate in the upcoming investor conferences in November
-
Apellis to Present New Data Supporting the Efficacy and Safety of Pegcetacoplan in PNH at the American Society of Hematology Annual Meeting
11/5/2020
Eight abstracts accepted for presentation emphasize the potential of targeted C3 therapy to elevate the standard of care in paroxysmal nocturnal hemoglobinuria (PNH)
-
Apellis Pharmaceuticals Reports Third Quarter 2020 Financial Results
11/2/2020
Strategic collaboration announced with Sobi for global co-development and exclusive ex-U.S. commercialization rights for systemic pegcetacoplan
-
Apellis and Sobi Enter Collaboration for Global Co-development and Ex-US Commercialization of Systemic Pegcetacoplan in Rare Diseases with Urgent Need for New Treatments
10/27/2020
Sobi obtains global co-development and exclusive ex-U.S. commercialization rights for systemic pegcetacoplan, a targeted C3 therapy
-
Apellis Announces 18-Month Data from Phase 1b Study of Pegcetacoplan in Patients with Geographic Atrophy (GA)
10/19/2020
First data for 18 months of treatment with intravitreal pegcetacoplan demonstrates continued slowing of GA lesion growth beyond 12 months
-
Apellis Announces New Data Demonstrating Correlation between Complement Activation and COVID-19 Severity
10/15/2020
Ina Phase 1/2interventional study, preliminary open-label safety resultsin first six patientssupport advancementof APL-9, an investigational targeted C3 therapy, for severe COVID-19; additional 60-patient randomized, double-blind, controlled study cohort is currently enrolling
-
Apellis to Present Positive Results from the Phase 2 DISCOVERY Study of Pegcetacoplan in C3 Glomerulopathy (C3G) at ASN Kidney Week
10/9/2020
Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that positive results from the Phase 2 DISCOVERY study evaluating pegcetacoplan, a targeted C3 therapy, in patients with C3 glomerulopathy (C3G) will be presented at the American Society of Nephrology (ASN) Kidney Week on October 22, 2020.
-
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Oct 07, 2020
10/7/2020
Apellis Pharmaceuticals, Inc., a global biopharmaceutical company pioneering targeted C3 therapies, announced that the company approved the grant of equity awards to four new employees with grant date of October 1, 2020, as equity inducement awards outside of the company's 2017 Stock Incentive Plan and material to the employees’ acceptance of employment with the company.
-
Biopharma companies wrapped up September and headed into October with plenty of clinical trial news. Here’s a look.
-
Apellis Initiates Registrational Programs of Pegcetacoplan in Patients with C3G / IC-MPGN and ALS, Rare Diseases with High Unmet Need
10/5/2020
Apellis Pharmaceuticals, Inc. announced that it has initiated registrational programs of pegcetacoplan, a targeted C3 therapy, for people living with C3 glomerulopathy or immune complex membranoproliferative glomerulonephritis, rare diseases that can lead to kidney failure within five to 10 years, and amyotrophic lateral sclerosis, a devastating neurodegenerative disease that leads to progressive muscle weakness and paralysis.
-
Apellis Announces New Analysis Demonstrating Targeted C3 Therapy Pegcetacoplan Slows Progression of Early Disease in Patients with Geographic Atrophy (GA)
10/3/2020
Post hoc analysis of Phase 2 FILLY study shows 39% reduction in rate of progression from nascent GA, an earlier form of disease, to GAin patients treated with pegcetacoplan monthly vs. sham
-
Apellis Pharmaceuticals to Present at Stifel’s 2020 Immunology and Inflammation Virtual Summit
9/24/2020
Apellis Pharmaceuticals , Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that the company will present at Stifel’s 2020 Immunology and Inflammation Virtual Summit on Thursday, October 1, 2020 at 9:00 a.m. ET. Cedric Francois, M.D., Ph.D., co-founder and chief executive officer of Apellis, will participate in a panel discussion titled “The Evolution of Complement Targeted Therap
-
Apellis Announces Late-Breaking Presentation of Targeted C3 Therapy Pegcetacoplan in Patients with Geographic Atrophy (GA) at EURETINA 2020
9/21/2020
New analysis of age-related macular degeneration (AMD) progression in Phase 2 FILLY study accepted as late-breaking oral presentation at European Society of Retina Specialists Congress (EURETINA) Pegcetacoplan targets C3, and has the potential to control the irreversible lesion growth in GA, an advanced form of AMD and leading cause of blindness WALTHAM, Mass., Sept. 21, 2020 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals , Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in
-
Apellis Announces Submission of Pegcetacoplan Marketing Applications to FDA and EMA for Patients with PNH
9/15/2020
Apellis Pharmaceuticals, Inc. announced that the company has submitted a New Drug Application to the U.S. Food and Drug Administration and a Marketing Authorization Application to the European Medicines Agency for pegcetacoplan for the treatment of paroxysmal nocturnal hemoglobinuria in the United States and European Union, respectively.
-
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Sep 04, 2020
9/4/2020
Apellis Pharmaceuticals, Inc., a global biopharmaceutical company pioneering targeted C3 therapies, announced that the company approved the grant of equity awards to four new employees with grant date of September 1, 2020, as equity inducement awards outside of the company's 2017 Stock Incentive Plan and material to the employees’ acceptance of employment with the company.
-
Apellis Pharmaceuticals to Present at Upcoming Investor Conferences - Sep 02, 2020
9/2/2020
Apellis Pharmaceuticals, Inc. a global biopharmaceutical company pioneering targeted C3 therapies, announced that the company will participate in the following upcoming investor conferences in September
-
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Aug 21, 2020
8/21/2020
Apellis Pharmaceuticals, Inc., a global biopharmaceutical company pioneering targeted C3 therapies, announced that the company approved the grant of an equity award to a new employee with a grant date of August 17, 2020, as an equity inducement award outside of the company's 2017 Stock Incentive Plan and material to the employee’s acceptance of employment with the company.
-
Apellis Pharmaceuticals Reports Second Quarter 2020 Financial Results
7/31/2020
New Drug Application (NDA) and Marketing Authorization Application (MAA) Submissions for Pegcetacoplan in Paroxysmal Nocturnal Hemoglobinuria (PNH) Planned for the Second Half of 2020